Biofusion sells portfolio companies to Morvus

Two portfolio companies of technology transfer business Biofusion have been sold to a privatelyowned pharmaceutical company just days after Biofusion raised its equity holdings in both companies to 50%. The sales of Cardiff Biologicals and Cardiff ProTides to Morvus Technology means that Biofusion now has a remaining portfolio of 23 companies from its partnerships with Sheffield and Cardiff universities.

Leave a Reply